Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
This approval is an important milestone for people living with obesity and cardiovascular disease, as the SELECT data demonstrated that Wegovy has the potential to prolong lives by addressing some of the leading causes of preventable deaths by reducing the risks of cardiovascular events.
In a follow-up proof-of-concept study by Aviles-Olmos et al., the longevity of motor and non-motor effects were assessed up to 24 months after the trial
Several licensed options are currently available in the UK, including semaglutide 2.4 mg (Wegovy), tirzepatide (Mounjaro), orlistat, liraglutide 3 mg (Saxenda), and naltrexone/bupropion (Mysimba)
Updates Ozempic (semaglutide) Pakket Waar kunnen we leveren
US$ 21.92
US$ 29.20
US$ 29.84
